CS
VRDN icon

Candriam SCA’s Viridian Therapeutics VRDN Stock Holding History

Candriam SCA’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.9M Sell
711,739
-73,359
-9% -$2.18M 0.07% 234
2025
Q4 		$24.4M Sell
785,098
-75,134
-9% -$2.06M 0.12% 168
2025
Q3 		$18.6M Sell
860,232
-2,041
-0.2% -$36.8K 0.1% 190
2025
Q2 		$12.1M Sell
862,273
-18,157
-2% -$246K 0.07% 221
2025
Q1 		$11.9M Buy
880,430
+149,209
+20% +$2.54M 0.07% 219
2024
Q4 		$14M Sell
731,221
-18,583
-2% -$404K 0.08% 218
2024
Q3 		$17.1M Hold
749,804
– – 0.1% 204
2024
Q2 		$9.75M Buy
749,804
+469,804
+168% +$6.5M 0.06% 254
2024
Q1 		$4.9M Buy
+280,000
New +$5.43M 0.03% 344

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return